Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Launched by GLAXOSMITHKLINE · Aug 30, 2010

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.
• • Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.
• • The subject has a radiographically measurable tumor.
• • The subject is able to carry out daily life activities without difficulty.
• • The subject is able to swallow and retain oral medication.
• • The subject does not have significant side effects from previous anti-cancer treatment.
• • The subject has adequate organ and blood cell counts.
• • Sexually active subjects must use medically acceptable methods of contraception during the course of the study.
• Exclusion Criteria:
• • The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.
• • The subject has a brain tumor.
• • Current severe, uncontrolled systemic disease.
• • History of clinically significant heart, lung, or eye/vision problems.
• • The subject has high blood pressure that is not well-controlled with medication.
• • The subject has a permanent pacemaker.
• • The subject is pregnant or breastfeeding.
• • Positive for Hepatitis B, Hepatitis C, or HIV.